10X GENOMICS INC-CLASS A (TXG) Stock Price, Forecast & Analysis

NASDAQ:TXG • US88025U1097

19.1 USD
+0.21 (+1.11%)
At close: Feb 24, 2026
19.15 USD
+0.05 (+0.26%)
After Hours: 2/24/2026, 8:00:01 PM

TXG Key Statistics, Chart & Performance

Key Statistics
Market Cap2.42B
Revenue(TTM)642.82M
Net Income(TTM)-76.32M
Shares126.55M
Float114.31M
52 Week High23.56
52 Week Low6.78
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.43
PEN/A
Fwd PEN/A
Earnings (Next)05-06
IPO2019-09-12
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
TXG short term performance overview.The bars show the price performance of TXG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

TXG long term performance overview.The bars show the price performance of TXG in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 60

The current stock price of TXG is 19.1 USD. In the past month the price decreased by -15.11%. In the past year, price increased by 78.67%.

10X GENOMICS INC-CLASS A / TXG Daily stock chart

TXG Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to TXG. When comparing the yearly performance of all stocks, TXG is one of the better performing stocks in the market, outperforming 89.09% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
TXG Full Technical Analysis Report

TXG Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to TXG. TXG has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TXG Full Fundamental Analysis Report

TXG Financial Highlights

Over the last trailing twelve months TXG reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 71.71% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.43%
ROE -9.72%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%67.5%
Sales Q2Q%0.61%
EPS 1Y (TTM)71.71%
Revenue 1Y (TTM)5.25%
TXG financials

TXG Forecast & Estimates

21 analysts have analysed TXG and the average price target is 18.43 USD. This implies a price decrease of -3.49% is expected in the next year compared to the current price of 19.1.

For the next year, analysts expect an EPS growth of -122.99% and a revenue growth -3.48% for TXG


Analysts
Analysts69.52
Price Target18.43 (-3.51%)
EPS Next Y-122.99%
Revenue Next Year-3.48%
TXG Analyst EstimatesTXG Analyst Ratings

TXG Ownership

Ownership
Inst Owners107.99%
Ins Owners1.6%
Short Float %14.28%
Short Ratio6.59
TXG Ownership

TXG Latest News, Press Relases and Analysis

All TXG news

TXG Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
TMO THERMO FISHER SCIENTIFIC INC20.77194.032B
DHR DANAHER CORP24.63149.099B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28142.4147.173B
A AGILENT TECHNOLOGIES INC20.5535.129B
MTD METTLER-TOLEDO INTERNATIONAL29.8428.325B
IQV IQVIA HOLDINGS INC12.627.528B
WAT WATERS CORP22.5519.513B
ILMN ILLUMINA INC23.7418.418B
WST WEST PHARMACEUTICAL SERVICES31.2617.569B
MEDP MEDPACE HOLDINGS INC26.3112.535B

About TXG

Company Profile

TXG logo image 10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

Company Info

10X GENOMICS INC-CLASS A

6230 Stoneridge Mall Road

Pleasanton CALIFORNIA 94588 US

CEO: Serge Saxonov

Employees: 1306

TXG Company Website

TXG Investor Relations

Phone: 13026587581

10X GENOMICS INC-CLASS A / TXG FAQ

Can you describe the business of 10X GENOMICS INC-CLASS A?

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.


What is the stock price of 10X GENOMICS INC-CLASS A today?

The current stock price of TXG is 19.1 USD. The price increased by 1.11% in the last trading session.


What is the dividend status of 10X GENOMICS INC-CLASS A?

TXG does not pay a dividend.


What is the ChartMill technical and fundamental rating of TXG stock?

TXG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Which stock exchange lists TXG stock?

TXG stock is listed on the Nasdaq exchange.


What do analysts say about 10X GENOMICS INC-CLASS A (TXG) stock?

21 analysts have analysed TXG and the average price target is 18.43 USD. This implies a price decrease of -3.49% is expected in the next year compared to the current price of 19.1.


What is the employee count for TXG stock?

10X GENOMICS INC-CLASS A (TXG) currently has 1306 employees.